Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Molecular Partners presents positive data from ongoing Phase 1/2a trial

In English
Bio-Technopark Schlieren-ZürichOffizielles

Molecular Partners announces planned extension of Cash Runway

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Calling all visionary female researchers!

Do you have an innovative idea that could change the world?  The feminno program is here to help you bring that vision to life! Join a dynamic community of like-minded women and gain access to experienced mentors who will guide you in refining and launching your startup.
 
Why wait for the perfect moment? This is your chance to turn passion into progress. Apply now and take the next step in your entrepreneurial journey with confidence and support. Join the 10- days feminno training and embark on a journey of discovery and growth. We teach you all you need to get started with your spin-off!
 
 
 
Apply now here by July 31, 2025: https://blogs.ethz.ch/feminno/application/
Kontaktieren
Aktiv
Bio-Technopark Schlieren-ZürichOffizielles

InSphero and Hesperos Announce Strategic Collaboration

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

InSphero Expands Through Strategic Agreement with Tessara Therapeutics

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Biognosys Launches Spectronaut 20 and SpectroMine 5

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Araris, Novago and Tolremo are nominated for Strüngmann Award

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Positive Phase 2 trial interim analysis for denovoSkin™ in pediatric burn pat.

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

GlycoEra receives 130 million dollars from investors

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles